V
Valeritas
Innovative peptide-based therapeutics for metabolic and rare diseases, advancing late-stage development programs
About Valeritas
Valeritas is a pharmaceutical company specializing in the development of innovative peptide-based therapeutics aimed at treating metabolic and rare diseases. The company operates in the biopharmaceutical market, focusing on creating next-generation peptide medicines that address significant unmet medical needs. Valeritas serves patients suffering from conditions such as diabetes, congenital hyperinsulinism, and short bowel syndrome, among others. The business model revolves around research and development, advancing its proprietary peptide platform through various clinical stages, including Phase 3 trials for some of its key programs. Revenue is generated through the commercialization of its developed therapies, partnerships, and licensing agreements. The company is committed to transforming lives by providing advanced therapeutic solutions and has a robust pipeline of products in late-stage development.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2017
News
Open roles
Valeritas in the Bridgewater Township ecosystem
The Valeritas office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
U.S. Venture Partners
MPM BioImpact
Pitango Venture Capital
Abingworth
HLM Venture Partners- OVOnset Ventures
- AVAdvanced Technology Ventures
Series B and later5 investors entered at this stage
- AIAgate Medical Investments
CHL Medical Partners
Welsh, Carson, Anderson & Stowe
Kaiser Permanente Ventures- CLCRG LP
Source: Dealroom Talent Intelligence.
See Valeritas on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


